Advanced Search

 

Study ID Status Title Patient Level Data
111419 Completed XP068: A Phase 1, Open-Label, Fed, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XP13512 (GSK1838262) Sustained Release (SR) Tablets Co-administered with Cimetidine in Healthy Adult Subjects
111420 Completed XP069: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation, Crossover Study of the Safety, Tolerability, and Pharmacokinetics of Oral XP13512 (GSK1838262) in Healthy Adult Subjects
111421 Completed XP078: A Randomized, Double-Blind, Placebo-Controlled, Four-Period Crossover Study To Evaluate the Effect of XP13512 (GSK1838262) on Cardiac Repolarization by Thorough Analysis of QTc Effect in Healthy Adult Subjects
111422 Completed XP086: A Phase 1, Randomized, Open-label, Formulation Comparison Study of the Pharmacokinetics, Safety, and Tolerability of XP13512 Extended Release (ER) Tablet Formulations and Neurontin® in Healthy Adult Male Subjects
111423 Completed XP087: A Phase 1, Randomized, Crossover, Open-label, Food Effect Comparison Study of the Pharmacokinetics, Safety, and Tolerability of XP13512 (GSK1838262) Sustained Release (SR) Tablet Formulation in Healthy Adult Subjects
111426 Completed Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium
111433 Completed Clinical Evaluation of eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An extension study of eltrombopag in subjects, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study TRA108109 (NCT00540423)-<Phase III Study>
111436 Completed Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT) Study Listed on ClinicalStudyDataRequest.com
111438 Active, Not Recruiting A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
111442 Completed Evaluation of effectiveness of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A against invasive disease Study Listed on ClinicalStudyDataRequest.com
111443 Completed Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules Study Listed on ClinicalStudyDataRequest.com
111444 Completed Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as post-consolidation therapy in adult patients with Acute Myeloid Leukemia
111451 Completed A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected with HIV
111454 Completed Non-inferiority study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A using different formulations. Study Listed on ClinicalStudyDataRequest.com
111459 Completed XP044: A Phase 1, Randomized, Cross-Over, Fed/Fasted Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Two Oral Sustained- Release Formulations of XP13512 (GSK1838262) in Healthy Adult Subjects
111460 Completed A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
111461 Completed A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.
111462 Completed A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients with Restless Legs Syndrome
111463 Completed A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients with Restless Legs Syndrome
111473 Completed Clinical activity, safety and immunogenic properties of cancer immunotherapeutic GSK2132231A in patients with unresectable and progressive metastatic cutaneous melanoma
111476 Completed GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma Study Listed on ClinicalStudyDataRequest.com
111482 Terminated GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma
111485 Completed VEG111485: A Phase I, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on Cardiac Conduction in Subjects with Solid Tumors
111490 Completed An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.
111491 Completed XP057: A Randomized, Cross-Over, Single-Dose Pharmacokinetic Study Assessing Two Oral Sustained Release Formulations of XP13512 (GSK1838262) in Healthy Adult Subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.